Esophageal squamous cell carcinoma (ESCC) has a consistently high incidence and poor prognosis. The RNA-binding protein insulin-like growth factor 2-binding protein 3 (IGF2BP3) has been implicated in the progression of various malignant tumors. However, the contribution of IGF2BP3 in ESCC and its underlying molecular mechanisms remain elusive. Here, we found that IGF2BP3 was upregulated in ESCC tissues, and elevated IGF2BP3 expression correlates with reduced overall survival. Through gain- and loss-of-function assays, IGF2BP3 significantly enhanced ESCC cell proliferation and migration in vitro and accelerated tumor growth and metastasis in vivo. Mechanistically, IGF2BP3 directly binds to multiple ribosomal protein L (RPL) mRNAs (e.g., RPL12, RPL8, RPL17) and enhances their stability, thereby promoting ribosomal assembly and improving global translation efficiency. This leads to substantial upregulation of oncoproteins such as c-Myc and β-catenin. Collectively, our findings reveal an oncogenic role of IGF2BP3 in ESCC progression and highlight it as a promising molecular target for further therapeutic exploration in ESCC.
Gu-Ha A-Lai, Shuangyan Tan, Wenrong Liu et al.· Biochimica et Biophysica Act...· 0 citations
Acquired resistance to third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) presents a formidable challenge in the treatment of non-small cell lung cancer (NSCLC). Despite the remarkable efficacy of these agents, resistance inevitably develops, typically within approximately 10 months of treatment initiation. This review elucidates the multifaceted mechanisms driving this resistance, broadly categorized into on-target EGFR-dependent alterations and off-target EGFR-independent bypass pathway activations. On-target mechanisms include the emergence of tertiary EGFR mutations, most notably C797S, which disrupts TKI binding. Off-target mechanisms encompass the activation of alternative signaling pathways such as MET and HER2/HER3 amplification, as well as histological transformations and complex changes within the tumor microenvironment. Furthermore, recent discoveries highlight the role of epigenetic dysregulation and metabolic reprogramming in fostering resistance. To counter this pervasive adaptability, advanced diagnostic methodologies, including liquid biopsy and high-resolution omics technologies, are crucial for real-time molecular profiling. The field is actively exploring emerging combination therapeutic strategies to circumvent these diverse resistance pathways, aiming to prolong clinical benefits and improve patient outcomes. The persistent emergence of resistance underscores that current targeted therapies, while revolutionary, are primarily disease-modifying rather than curative, necessitating continuous innovation to overcome the inherent biological challenge of tumor adaptability and heterogeneity.
Gu-Ha A-Lai, Lian Li, G. Ma et al.· Frontiers in Cell and Develo...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
